Bank of Montreal Can Makes New $248,000 Investment in Guardant Health, Inc. (NASDAQ:GH)

Bank of Montreal Can acquired a new position in Guardant Health, Inc. (NASDAQ:GH - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 8,118 shares of the company's stock, valued at approximately $248,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of GH. Vanguard Group Inc. increased its holdings in Guardant Health by 3.0% in the fourth quarter. Vanguard Group Inc. now owns 12,052,551 shares of the company's stock valued at $368,205,000 after buying an additional 350,606 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its position in Guardant Health by 19.4% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,464,213 shares of the company's stock worth $44,732,000 after buying an additional 238,037 shares in the last quarter. Nikko Asset Management Americas Inc. boosted its position in shares of Guardant Health by 15.6% during the 4th quarter. Nikko Asset Management Americas Inc. now owns 1,464,213 shares of the company's stock valued at $44,732,000 after acquiring an additional 197,729 shares during the last quarter. Norges Bank purchased a new stake in shares of Guardant Health in the 4th quarter valued at approximately $36,438,000. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Guardant Health by 1.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,016,533 shares of the company's stock valued at $31,055,000 after acquiring an additional 13,395 shares during the last quarter. Institutional investors and hedge funds own 92.60% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. JPMorgan Chase & Co. increased their target price on shares of Guardant Health from $50.00 to $55.00 and gave the stock an "overweight" rating in a research note on Friday, February 21st. Stephens restated an "overweight" rating and set a $55.00 target price on shares of Guardant Health in a research note on Wednesday, March 26th. Piper Sandler boosted their price target on shares of Guardant Health from $34.00 to $50.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Raymond James reissued an "outperform" rating and issued a $59.00 price objective (up from $39.00) on shares of Guardant Health in a report on Friday, February 21st. Finally, Stifel Nicolaus raised their price target on Guardant Health from $45.00 to $53.00 and gave the stock a "buy" rating in a report on Friday, February 21st. Twenty analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $49.00.

Guardant Health Price Performance

Shares of NASDAQ GH traded down $2.30 on Wednesday, hitting $47.23. The company's stock had a trading volume of 3,562,768 shares, compared to its average volume of 2,156,370. The stock has a 50 day moving average of $43.48 and a 200-day moving average of $37.75. Guardant Health, Inc. has a 12-month low of $17.85 and a 12-month high of $50.89. The company has a market capitalization of $5.83 billion, a price-to-earnings ratio of -13.27 and a beta of 1.45.

Guardant Health (NASDAQ:GH - Get Free Report) last announced its earnings results on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.15). Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The company had revenue of $201.81 million for the quarter, compared to analyst estimates of $192.50 million. Sell-side analysts expect that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.